In 2019, the domestic anti-PD-1 antibody camrelizumab was first approved in China and subsequently applied for various malignancies, including B cell lymphoma, oesophageal squamous cell carcinoma and hepatocellular carcinoma (Markham and Keam, 2019). The gene discussed is PDCD1; the disease is hepatocellular carcinoma.